CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
APAC
CANADA

About Us

Conference

Partner With Us

  • Europe
    • US
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Biotech
    Cancer Immunotherapy
    Cell and Gene Therapy Companies
    Clinical Trial Management
    Drug Discovery and Development
    Genomics
    Therapeutics
    Women's Health
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    CDMO
    Clinical Laboratory Services
    CRO
    Supplements
  • Business Services
    Clinical Research Training
    Life Science Consulting
    Life Science Logistics
    Life Science Marketing
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Schwabe Group

Alessio Rossi, Product Development Manager

Enhancing the Homoeopathic Ecosystem in Europe

Alessio Rossi

Alessio Rossi

Homoeopathy in Europe faces challenges in mainstream healthcare, but can be strengthened through strong relationships, interprofessional education, public-private partnerships, and knowledge exchange platforms.


Grounded in the principle of "like cures like," homoeopathy has emerged as a prominent medical discipline, experiencing a consistent rise in popularity across Europe, marked by an estimated 150 million consultations annually. Nevertheless, the acceptance of homoeopathy by conventional medical institutions and its assimilation into mainstream healthcare remain contentious topics. Navigating this challenging landscape necessitates the establishment of robust relationships and collaborations within the European homoeopathic community to fortify its presence and viability.


Promising Avenues for Collaboration


Engaging in interprofessional education is crucial for cultivating mutual respect, understanding, and collaboration between homoeopathic and conventional healthcare professionals, thereby enhancing patient care. To facilitate this, joint training programs should be established. Additionally, the formation of pan-European research consortia, involving universities, homoeopathic hospitals, and conventional research institutions, presents an opportunity to harness collective expertise and resources for the conduct of high-quality clinical trials. Public-private partnerships are instrumental in integrating homoeopathy into public health programs, and collaborative efforts between homoeopathic practitioners, patient organisations, and government agencies can effectively address specific healthcare needs. Moreover, the establishment of knowledge exchange platforms, particularly online, can serve as valuable tools for sharing research findings, best practices, and educational resources, ultimately bridging the gap between homoeopathic and conventional healthcare communities.


The Horizon 2020 research program of the European Union has allocated funding to numerous projects investigating the efficacy of homoeopathy, particularly in the realms of mental health and palliative care. 


In 2021, the Committee on Bioethics of the Council of Europe released a report recognising the significance of complementary and alternative medicines, including homoeopathy, and advocated for their integration into mainstream healthcare systems. On a national level, initiatives such as the Prince of Wales Foundation for Integrated Health in the UK and the German Central Association of Homeopathic Doctors are actively championing research and fostering collaboration within their respective countries. These efforts underscore a growing recognition and support for exploring the potential benefits of homoeopathy in diverse healthcare contexts.


Technology emerges as a pivotal force in fortifying the homoeopathic ecosystem through various channels. Telemedicine platforms, for instance, serve as catalysts in enhancing access to homoeopathic care, particularly in underserved regions, by enabling online consultations. Additionally, digital education platforms contribute significantly by offering practitioners continuous learning opportunities through online courses and resources. Collaborative research efforts are further facilitated by shared databases, fostering seamless collaboration and data analysis within the homoeopathic community. Furthermore, patient portals on online platforms empower individuals to actively manage their health, fostering a direct and efficient connection with homoeopathic practitioners. In essence, technology acts as a transformative agent, elevating the efficiency and accessibility of homoeopathic healthcare.


By cultivating strong partnerships and fostering collaborations in the realms of research, education, policy, and public awareness, the European homoeopathic ecosystem is poised to overcome present challenges and flourish in the future. Through the promotion of a collaborative environment and a commitment to evidence-based practices, homoeopathy can authentically position itself as a valuable complement to conventional medicine. This approach extends the range of treatment alternatives available to patients, contributing to a more comprehensive approach to healthcare.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review Europe
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review Europe. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesrevieweurope.com/leadership-perspective/enhancing-the-homoeopathic-ecosystem-in-europe-nwid-1717.html